NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
36 trialsNCT04633122 2026-04-03
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT06208748 2025-10-31
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Sarcoma Alliance for Research through Collaboration
Phase 2 Active not recruiting
NCT05366816 2025-09-09
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
Phase 2 Recruiting
NCT00961571 2025-02-12
Sunitinib and Capecitabine for First Line Colon Cancer
Georgetown University
Phase 2 Terminated
NCT00936832 2022-08-30
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Withdrawn
NCT03170180 2022-06-15
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
Samsung Medical Center
Phase 2 Completed
NCT02402062 2020-07-27
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT02713763 2020-03-04
RESUNET
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01396148 2019-03-27
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Pfizer
Phase 2 Completed
NCT00806663 2019-02-06
FOLFIRI and Sunitinib in Metastatic Colorectal Cancer
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT00891878 2018-07-24
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00787787 2017-06-01
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
University of Washington
Phase 2 Terminated
NCT00524316 2017-05-09
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00400114 2017-05-08
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00702884 2017-03-21
Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00730353 2017-03-16
Sutent + Taxol for Advanced Esophageal Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT01718327 2017-01-31
SUN-CK
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Completed
NCT01803503 2016-06-22
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors
National University Hospital, Singapore
Phase 2 Unknown
NCT01215578 2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT00226811 2015-03-30
An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy
Pfizer
Phase 2 Completed
NCT00361309 2014-03-18
SU011248 in Advanced Hepatocellular Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT01215565 2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT00397787 2013-06-04
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
National Cancer Institute (NCI)
Phase 2 Completed
NCT01238055 2013-04-09
Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer
Samsung Medical Center
Phase 2 Completed
NCT00609622 2012-10-11
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
Pfizer
Phase 2 Terminated
NCT00400569 2012-08-28
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00514228 2012-06-26
Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Swiss Cancer Institute
Phase 2 Completed
NCT00495625 2012-03-27
Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00967603 2012-02-01
PACT-12
IRCCS San Raffaele
Phase 2 Completed
NCT00673504 2011-12-01
First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT00668863 2011-10-17
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
Pfizer
Phase 2 Completed
NCT00411151 2011-01-20
Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
Johannes Gutenberg University Mainz
Phase 2 Completed
NCT00247676 2010-02-18
An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
Pfizer
Phase 2 Completed
NCT00137449 2009-09-15
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
Pfizer
Phase 2 Completed
NCT00077987 2007-01-11
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
Pfizer
Phase 2 Completed